Idiopathic Pulmonary Fibrosis Clinical Trial
Official title:
Prevalence and Impact on Quality of Life of Airway Disease in Patients With Idiopathic Pulmonary Fibrosis
The investigators assess the prevalence of airway disease associated with idiopathic pulmonary fibrosis in Korea, and evaluate the effect of these airway diseases on the symptoms and quality of life of patients with idiopathic pulmonary fibrosis.
Status | Recruiting |
Enrollment | 100 |
Est. completion date | February 28, 2020 |
Est. primary completion date | February 28, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A and older |
Eligibility |
Inclusion Criteria: - IPF patients Exclusion Criteria: - Patients on systemic steroid - Patients with acute exacerbation within the last 6 months - PFT+BDR, MBPT contra-indication - SpO2 < 90% |
Country | Name | City | State |
---|---|---|---|
Korea, Republic of | Seoul National University Hospital | Seoul |
Lead Sponsor | Collaborator |
---|---|
Seoul National University Hospital |
Korea, Republic of,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of participants who have asthma combined with idiopathic pulmonary fibrosis | Confirmation of asthma : pulmonary function test with bronchodilator response or Methacholine provocation test | Through study completion, an average of 2 year | |
Primary | Number of participants who have COPD combined with idiopathic pulmonary fibrosis | Confirmation of COPD : pulmonary function test with bronchodilator response | Through study completion, an average of 2 year | |
Primary | Number of participants who have Eosinophilic bronchitis combined with idiopathic pulmonary fibrosis | Confirmation of Eosinophilic bronchitis : pulmonary function test with bronchodilator response, induced sputum | Through study completion, an average of 2 year | |
Secondary | The difference of CAT scores between patients with airway disease and those without airway disease. | Quality of life : COPD assessment test(CAT) | baseline and after treating the airway disease for 6~8 weeks | |
Secondary | The difference of SGRQ scores to assess quality of life between patients with airway disease and those without airway disease. | Quality of life : St George's Respiratory Questionnaire(SGRQ) | baseline and after treating the airway disease for 6~8 weeks | |
Secondary | The difference of mMRC scores to assess symptom severity between patients with airway disease and those without airway disease. | Symptom severity : mMRC | baseline and after treating the airway disease for 6~8 weeks | |
Secondary | The difference of distance of 6MWT to assess symptom severity between patients with airway disease and those without airway disease. | Symptom severity : 6 minute walking test(6MWT) | baseline and after treating the airway disease for 6~8 weeks | |
Secondary | The difference of EQ-5D-VAS scores to assess symptom severity between patients with airway disease and those without airway disease. | Symptom severity : EQ-5D-VAS | baseline and after treating the airway disease for 6~8 weeks | |
Secondary | The difference of CQLQ scores to assess symptom severity between patients with airway disease and those without airway disease. | Symptom severity : Cough Quality-of-Life Questionnaire(CQLQ) | baseline and after treating the airway disease for 6~8 weeks | |
Secondary | Checking the improvement of CAT score to assess the quality of life between patients with airway disease and those without airway disease | Quality of life : COPD assessment test(CAT) | After treating the airway disease for 6~8 weeks | |
Secondary | Checking the improvement of SGRQ score to assess the quality of life between patients with airway disease and those without airway disease | Quality of life : St George's Respiratory Questionnaire(SGRQ) | After treating the airway disease for 6~8 weeks | |
Secondary | Checking the improvement of mMRC scores to assess symptom severity between patients with airway disease and those without airway disease | Symptom severity : mMRC | After treating the airway disease for 6~8 weeks | |
Secondary | Checking the improvement of distance of 6MWT to assess symptom severity between patients with airway disease and those without airway disease | Symptom severity : 6 minute walking test(6MWT) | After treating the airway disease for 6~8 weeks | |
Secondary | Checking the improvement of EQ-5D-VAS score to assess symptom severity between patients with airway disease and those without airway disease | Symptom severity : EQ-5D-VAS | After treating the airway disease for 6~8 weeks | |
Secondary | Checking the improvement of CQLQ to assess symptom severity between patients with airway disease and those without airway disease | Symptom severity : Cough Quality-of-Life Questionnaire(CQLQ) | After treating the airway disease for 6~8 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05984992 -
The First-in-human Study of SRN-001 in Healthy Participants
|
Phase 1 | |
Active, not recruiting |
NCT04312594 -
Study of Jaktinib Hydrochloride Tablets in Participants With Idiopathic Pulmonary Fibrosis
|
Phase 2 | |
Recruiting |
NCT03865927 -
GKT137831 in IPF Patients With Idiopathic Pulmonary Fibrosis
|
Phase 2 | |
Completed |
NCT03979430 -
Early Detection of Acute Exacerbation in Patients With Idiopathic Lung Fibrosis - a Pilot Study
|
N/A | |
Enrolling by invitation |
NCT04905693 -
Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis
|
Phase 3 | |
Not yet recruiting |
NCT06241560 -
A Study in People With Idiopathic Pulmonary Fibrosis to Test Whether Pirfenidone Influences the Amount of BI 1015550 in the Blood
|
Phase 2 | |
Terminated |
NCT04419558 -
Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)
|
Phase 3 | |
Completed |
NCT03725852 -
A Clinical Study to Test How Effective and Safe GLPG1205 is for Participants With Idiopathic Pulmonary Fibrosis (IPF)
|
Phase 2 | |
Terminated |
NCT03573505 -
An Efficacy and Safety Study of BG00011 in Participants With Idiopathic Pulmonary Fibrosis
|
Phase 2 | |
Recruiting |
NCT04148157 -
Quality of Life in IPF - Patient and Physician Perceptions
|
||
Completed |
NCT03222648 -
Structured Exercise Training Programme in Idiopathic Pulmonary Fibrosis
|
N/A | |
Not yet recruiting |
NCT06422884 -
A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial)
|
Phase 2 | |
Completed |
NCT02268981 -
Effects of an Oxymizer® During Daytime in Patients With Pulmonary Fibrosis (IPF)
|
N/A | |
Completed |
NCT02257177 -
RCT (Randomized Control Trial) of TD139 vs Placebo in HV's (Human Volunteers) and IPF Patients
|
Phase 1/Phase 2 | |
Withdrawn |
NCT01524068 -
A MultiCenter Study of Combined PEX, Rituximab, and Steroids in Acute Idiopathic Pulmonary Fibrosis Exacerbations
|
Phase 2 | |
Enrolling by invitation |
NCT01382368 -
Acute Effect of Sildenafil on Exercise Tolerance and Functional Capacity in COPD, IPF and Post Pneumonectomy Patients
|
Phase 4 | |
Completed |
NCT01199887 -
Trial Of IW001 in Patients With Idiopathic Pulmonary Fibrosis
|
Phase 1 | |
Completed |
NCT01110694 -
Prospective Observation of Fibrosis in the Lung Clinical Endpoints Study
|
||
Active, not recruiting |
NCT02951416 -
Clinical Course of Interstitial Lung Diseases: European IPF Registry and Biobank
|
||
Terminated |
NCT00981747 -
Targeting Vascular Reactivity in Idiopathic Pulmonary Fibrosis
|
Phase 2/Phase 3 |